<- Go Home
Orgenesis Inc.
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
Market Cap
$8.0M
Volume
16.1K
Cash and Equivalents
$204.0K
EBITDA
-$24.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$878.0K
Profit Margin
97.66%
52 Week High
$10.80
52 Week Low
$0.87
Dividend
N/A
Price / Book Value
-0.31
Price / Earnings
-0.17
Price / Tangible Book Value
-0.22
Enterprise Value
$25.1M
Enterprise Value / EBITDA
-1.07
Operating Income
-$25.9M
Return on Equity
179.44%
Return on Assets
-68.49
Cash and Short Term Investments
$204.0K
Debt
$17.3M
Equity
-$23.9M
Revenue
$899.0K
Unlevered FCF
$9.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium